Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.580
-0.020 (-0.77%)
At close: Jul 3, 2025, 1:00 PM
2.600
+0.020 (0.78%)
After-hours: Jul 3, 2025, 4:50 PM EDT
BDTX Stock Forecast
Stock Price Forecast
The 6 analysts that cover BDTX stock have a consensus rating of "Strong Buy" and an average price target of $14.83, which forecasts a 474.81% increase in the stock price over the next year. The lowest target is $11 and the highest is $20.
Price Target: $14.83 (+474.81%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BDTX stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy Initiates $11 | Buy | Initiates | $11 | +326.36% | Jul 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $12 | Strong Buy | Maintains | $11 → $12 | +365.12% | Mar 18, 2025 |
| Stifel | Stifel | Strong Buy Maintains $16 → $15 | Strong Buy | Maintains | $16 → $15 | +481.40% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +326.36% | Nov 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +326.36% | Oct 9, 2024 |
Financial Forecast
Revenue This Year
n/a
from 137.98M
Revenue Next Year
n/a
EPS This Year
-0.05
from -1.27
EPS Next Year
-1.04
from -0.05
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 73.5M | n/a | 20.9M | ||
| Avg | 47.6M | n/a | 6.8M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -46.7% | - | - | ||
| Avg | -65.5% | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.28 | -0.84 | -0.81 | ||
| Avg | -0.05 | -1.04 | -1.21 | ||
| Low | -0.62 | -1.42 | -1.96 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.